imotuzumab in COVID-19

Phase 1

Not yet recruiting

• Conditions: COVID-19; SARS-CoV2; Coronavirus Infections; SARS Virus; Coronaviridae Infections; Betacoronavirus; Acute Disease; Critical Care

• Registration Number: RPCEC00000369
• Lead Sponsor: Center of Molecular Immunology (CIM)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-21
• Study Completion: 2021-08-31
• Results First Posted: 2021-09-30
• Last Update Posted: 2024-08-19

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1.- Any gender and skin color
2.- Age equal to or greater than 19 years
3.- Patients in a severe stage of COVID-19 of the disease defined by any of the following conditions:
- Patients who have SpO2 <94% or patients in need of oxygen therapy to maintain SO2> 93% or
- Patients with a PaO2 / FiO2 ratio <300 mm Hg or
- Patients with a respiratory rate> 30 inspirations / min,
- Patients with infiltrate in more than 50% of both lung fields

Exclusion Criteria

1.- Pregnant or lactating women.
2.-Under 19 years.

Study & Design

• Study Type: Interventional
• Study Design: Not specified